

Cardiogenic Shock Current Concepts and Improving Outcomes

Harmony R. Reynolds, MD; Judith S. Hochman, MD

Cardiogenic shock (CS) occurs in $\approx 5\%$ to 8% of patients hospitalized with ST-elevation myocardial infarction (STEMI). Recent research has suggested that the peripheral vasculature and neurohormonal and cytokine systems play a role in the pathogenesis and persistence of CS. Early revascularization for CS improves survival substantially. New mechanical approaches to treatment are available, and clinical trials are feasible even in this high-risk population. Most importantly, hospital survivors have an excellent chance for long-term survival with good quality of life. This review will outline the causes, pathophysiology, and treatment of CS with a focus on CS complicating myocardial infarction (MI). The case will be made for viewing CS as a serious disorder with a high early death rate, but one that is treatable and that, if approached aggressively, can result in full recovery.

Diagnosis and Causes

CS is a state of end-organ hypoperfusion due to cardiac failure. The definition of CS includes hemodynamic parameters: persistent hypotension (systolic blood pressure <80 to 90 mm Hg or mean arterial pressure 30 mm Hg lower than baseline) with severe reduction in cardiac index (<1.8 L \cdot min $^{-1}$ \cdot m $^{-2}$ without support or <2.0 to 2.2 L \cdot min $^{-1}$ \cdot m $^{-2}$ with support) and adequate or elevated filling pressure (eg, left ventricular [LV] end-diastolic pressure >18 mm Hg or right ventricular [RV] end-diastolic pressure >10 to 15 mm Hg). The diagnosis is usually made with the help of pulmonary artery (PA) catheterization; however, Doppler echocardiography may also be used to confirm elevation of LV filling pressures.¹ Hypoperfusion may be manifest clinically by cool extremities, decreased urine output, and/or alteration in mental status. Hemodynamic abnormalities form a spectrum that ranges from mild hypoperfusion to profound shock, and the short-term outcome is directly related to the severity of hemodynamic derangement.

MI with LV failure remains the most common cause of CS. It is critical to exclude complicating factors that may cause shock in MI patients. Chief among these are the mechanical complications: ventricular septal rupture, contained free wall rupture, and papillary muscle rupture. Mechanical complications must be strongly suspected in patients with CS complicating nonanterior MI, particularly a first MI. Echocardiography is the technique of choice to rule out these entities and

should be performed early unless the diagnosis is extensive anterior MI and the patient is undergoing prompt percutaneous coronary intervention (PCI). In addition, the detection of valvular disease before angiography may alter the revascularization approach.

Hemorrhage, infection, and/or bowel ischemia may contribute to shock in the setting of MI. As with mechanical complications, a high index of suspicion is required to make these diagnoses in MI patients, and survival may depend on timely recognition and treatment.

Any cause of acute, severe LV or RV dysfunction may lead to CS. Acute myopericarditis, tako-tsubo cardiomyopathy, and hypertrophic cardiomyopathy may all present with ST elevation, release of cardiac markers, and shock in the absence of significant coronary artery disease. Stress-induced cardiomyopathy, also known as apical ballooning or tako-tsubo cardiomyopathy, is a syndrome of acute LV dysfunction after emotional or respiratory distress that leads to CS in 4.2% of cases.² Acute valvular regurgitation, typically caused by endocarditis or chordal rupture due to trauma or degenerative disease, may also cause CS. Aortic dissection may lead to CS via acute, severe aortic insufficiency or MI. Acute stress in the setting of aortic or mitral stenosis can also cause shock. Cardiac tamponade or massive pulmonary embolism can present as cardiogenic shock without associated pulmonary congestion.

Incidence

After decades of remarkable stability in the incidence of CS, it appears that the incidence is on the decline in parallel with increasing rates of use of primary PCI for acute MI. CS continues to complicate approximately 5% to 8% of STEMI^{3,4} and 2.5% of non-STEMI cases.⁵ This translates to $40\,000$ to $50\,000$ cases per year in the United States.⁶ The routine use of troponin to define non-STEMI will result in a drop in this percentage as more MIs are detected but will not alter the total number of cases of CS.

Identification of Patients at Risk


The only way to prevent CS appears to be very early reperfusion therapy for MI. A randomized trial of early, in-ambulance thrombolysis versus primary PCI found no CS among patients assigned to prehospital thrombolysis.⁷ Among

From The Leon H. Charney Division of Cardiology, Cardiovascular Clinical Research Center, New York University School of Medicine, New York, NY. Correspondence to Judith S. Hochman, MD, New York University School of Medicine, 530 First Ave, SKI-9R, New York, NY 10016. E-mail Judith.Hochman@nyumc.org (Circulation. 2008;117:686-697.)

© 2008 American Heart Association, Inc.

Circulation is available at <http://circ.ahajournals.org>

DOI: 10.1161/CIRCULATIONAHA.106.613596



Randomized ALdactone Evaluation Study; ELITE II, Evaluation of Losartan In The Elderly II; COPERNICUS, Carvedilol Prospective RaNdOmized CUmulative Survival study; COMET, Carvedilol Or Metoprolol European Trial; and CHARM, Candesartan in Heart failure: Assessment of moRtality and Morbidity. Adapted from Ramanathan et al,¹⁰ with permission of the author.

Figure 2. Range of LVEF in studies of heart failure and in the SHOCK trial. Range of LVEF (mean±SD) is presented for a variety of trials of recent MI with asymptomatic or mildly symptomatic LV dysfunction or chronic HF. The range of LVEF in the SHOCK trial (mean±SD) overlaps with the range of LVEF in these trials, although LVEF in SHOCK was obtained on support measures. Note that REMATCH (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart failure) studied LVAD use as destination therapy. *Measured on support. CHF indicates congestive heart failure; EPHESUS, Eplerenone Post-acute myocardial infarction Heart failure Efficacy and Survival Study; CAPRICORN, Carvedilol Post infarction Survival Control in LV dysfunction; VALIANT, VALsartan In Acute myocardial infarction; DINAMIT, Defibrillator IN Acute Myocardial Infarction; MADIT II, Multicenter Automatic Defibrillator Implantation Trial II; RALES,

onstrated a small increase in LV end-diastolic volume in 2-week survivors of CS (15-mL change in median LV end-diastolic volume).²³ Contractile function can be assessed with echocardiography or LV angiography. In addition, the indwelling PA catheter allows ongoing evaluation of CO in response to changes in therapy and volume status. Diastolic function is more difficult to assess. It is likely that abnormalities of ventricular relaxation and compliance contribute to CS in some, if not all, cases.

Right Ventricle

RV dysfunction may cause or contribute to CS. Predominant RV shock represents only 5% of cases of CS complicating MI.²⁶ RV failure may limit LV filling via a decrease in CO, ventricular interdependence, or both. Treatment of patients with RV dysfunction and shock has traditionally focused on ensuring adequate right-sided filling pressures to maintain CO and adequate LV preload; however, patients with CS due to RV dysfunction have very high RV end-diastolic pressure, often >20 mm Hg.²⁶ This elevation of RV end-diastolic pressure may result in shifting of the interventricular septum toward the LV cavity, which raises left atrial pressure but impairs LV filling due to the mechanical effect of the septum bowing into the LV. This alteration in geometry also impairs LV systolic function.²⁷ Therefore, the common practice of aggressive fluid resuscitation for RV dysfunction in shock may be misguided. Inotropic therapy is indicated for RV failure when CS persists after RV end-diastolic pressure has been optimized. RV end-diastolic pressure of 10 to 15 mm Hg has been associated with higher output than lower or higher pressures,²⁸ but marked variability exists in optimal values. Inhaled nitric oxide (NO) may be useful to lower pulmonary vascular resistance and promote forward flow. Both pericardiectomy and creation of atrial septal defects have been used in extreme cases.

Shock due to isolated RV dysfunction carries nearly as high a mortality risk as LV shock.²⁶ The benefit of revascu-

larization was similar in the SHOCK registry for patients with primarily RV versus primarily LV dysfunction.

Peripheral Vasculature, Neurohormones, and Inflammation

Hypoperfusion of the extremities and vital organs is a hallmark of CS. The decrease in CO caused by MI and sustained by ongoing ischemia triggers release of catecholamines, which constrict peripheral arterioles to maintain perfusion of vital organs. Vasopressin and angiotensin II levels increase in the setting of MI and shock, which leads to improvement in coronary and peripheral perfusion at the cost of increased afterload, which may further impair myocardial function. Activation of the neurohormonal cascade promotes salt and water retention; this may improve perfusion but exacerbates pulmonary edema. The reflex mechanism of increased systemic vascular resistance (SVR) is not fully effective, as demonstrated by variable SVR, with median SVR during CS in the normal range despite vasopressor therapy in the SHOCK Trial.²⁹ In some patients, SVR may be low, similar to septic shock. In fact, sepsis was suspected in 18% of the SHOCK trial cohort, 74% of whom developed positive bacterial cultures.²⁹ SVR was lower in these patients, and low SVR preceded the clinical diagnosis of infection and culture positivity by days.

These findings are consistent with the observation that MI can cause the systemic inflammatory response syndrome (SIRS) and suggest that inappropriate vasodilation as part of SIRS results in impaired perfusion of the intestinal tract, which enables transmigration of bacteria and sepsis. SIRS is more common with increasing duration of shock,³⁰ even though levels of interleukin-6 and tumor necrosis factor- α have been found to be elevated on admission among MI patients who were initially in Killip class I and later developed CS.³¹ Cytokine levels rise more dramatically over the 24 to 72 hours after MI. Tumor necrosis factor- α and interleukin-6 have myocardial depressant action. Tumor ne-




Figure 3. Iatrogenic shock. The pathophysiology of iatrogenic shock that results from different scenarios of MI and pulmonary edema treatment is depicted. Acute pulmonary edema is a state of redistribution of intravascular volume into extracellular space in the lungs. When hemodynamic stability is tenuous, the additional decrease in plasma volume caused by diuretics in patients without prior heart failure may induce shock. Tachycardia is often compensatory for lower stroke volume but is not appreciated as such. Treatment with β -blockade lowers heart rate and stroke volume, leading to frank shock. Decompensation may also occur when patients who are reliant on compensatory vasoconstriction are treated with angiotensin-converting enzyme inhibitors, particularly intravenously and early. Nitrates would be expected to have a similar effect but did not in the only systematic study, which used oral, low-dose treatment. Volume expansion may be deleterious when used to excess or when RV filling pressure is already elevated, because the RV may

become volume overloaded with shift of the septum causing impairment in LV filling and contraction. CVP indicates central venous pressure; HTN, hypertension; PCWP, pulmonary capillary wedge pressure; RVEDP, RV end-diastolic pressure; and RVEDV, RV end-diastolic volume.

crosis factor- α also induces coronary endothelial dysfunction, which may further diminish coronary flow.³² Other circulating factors (complement, procalcitonin, neopterin, C-reactive protein, and others) have been reported to contribute to SIRS in CS. Despite a promising randomized phase 2 study, a trial of complement (C5) inhibition in patients with MI found that pexelizumab did not reduce the development of shock or mortality.^{33,34}

Excess NO may also contribute to SIRS. MI is associated with increased expression of inducible NO synthase, which leads to excess NO, which causes vasodilation, myocardial depression, and interference with catecholamine action. Although isoform-nonspecific NO synthase inhibitors appeared to improve hemodynamics and outcome in small studies of CS patients, *N*^G-monomethyl-L-arginine at the same dose and duration did not reduce mortality in a large multicenter trial.³⁵ *N*^G-monomethyl-L-arginine did, however, result in an early blood pressure rise in patients with persistent shock despite vasopressors and opening of the infarct artery, which suggests that excess NO contributes to hypotension.³⁶ Additional studies will be needed to test the hypothesis that prevention/treatment of SIRS or excess inducible NO synthase will improve outcomes.

CS May Be an Iatrogenic Illness

Approximately three fourths of patients with CS complicating MI develop shock after hospital presentation.^{4,37} In some, medication use contributes to the development of shock. Several different classes of medications used to treat MI have been associated with shock, including β -blockers, angiotensin-converting enzyme inhibitors, and morphine. Although early use of each of these medications is associated with only a small excess risk of CS, the large number of patients treated with these therapies translates into a substantial potential

number of events.^{38–41} The timing of CS (early after medication initiation) in the placebo-controlled, randomized trials of β -blockade and angiotensin-converting enzyme inhibition combined with their mechanisms of action indicate that they may contribute to CS development in those at high risk.

Diuretics may also cause or contribute to shock in patients with MI (Figure 3).^{42,43} As depicted in Figure 3, MI may lead to pulmonary edema even without a decrease in CO, because the earliest effect of ischemia is often a decrease in LV compliance. Redistribution of intravascular volume into the lungs leads to a net acute decrease in circulating plasma volume in those without prior heart failure. When high-dose diuretics are administered, plasma volume declines further. A trial of a low diuretic dose coupled with low-dose nitrates and positional measures to decrease preload (eg, seated position with legs down) should be attempted in patients with MI and pulmonary edema to avoid precipitating shock. Excess volume loading in patients with RV infarction may also cause or contribute to shock.

Treatment

General Support Measures

Antithrombotic therapy with aspirin and heparin should be given as routinely recommended for MI. Clopidogrel may be deferred until after emergency angiography, because on the basis of angiographic findings, coronary artery bypass grafting (CABG) may be performed immediately. Clopidogrel is indicated in all patients who undergo PCI, and on the basis of extrapolation of data from MI patients who were not in shock, it should also be useful in patients with shock as well. Negative inotropes and vasodilators (including nitroglycerin) should be avoided. Arterial oxygenation and near-normal pH should be maintained to minimize ischemia. Intensive insulin

therapy improves survival in hyperglycemic critically ill patients and is recommended for use in complicated MI.⁴⁴ There should be a low threshold to institute mechanical ventilation via mask or endotracheal tube. Positive end-expiratory pressure decreases preload and afterload. Mechanical ventilation also reduces work of breathing.

Hemodynamic Management

PA (Swan-Ganz) catheterization is frequently performed to confirm the diagnosis of CS, to ensure that filling pressures are adequate, and to guide changes in therapy. The best use of this technique is to establish the relationship of filling pressures to CO in the individual patient and supplement clinical assessment of responses with these data. Hemodynamic data, particularly cardiac power and stroke work index, have powerful short-term prognostic value.⁴⁵ There has been a decline in PA catheter use relating to controversy sparked by a prospective observational study that suggested that PA catheters were associated with poor outcome.⁴⁶ No such association has been shown in CS.⁴⁷

Individualized PA catheter use is recommended for severely hypotensive MI patients⁴⁴; however, many centers now choose to manage CS without PA catheterization. Clinical assessment with echocardiography is a reasonable alternative: Both PA systolic pressure and wedge pressure can be accurately estimated with Doppler echocardiography, and in particular, the finding of a short mitral deceleration time (≤ 140 ms) is highly predictive of pulmonary capillary wedge pressure ≥ 20 mm Hg in CS.²⁴ The clinical examination and chest radiograph are not reliable predictors of pulmonary capillary wedge pressure; neither detects elevation in 30% of CS patients.

Pharmacological Treatment

Pharmacological support includes inotropic and vasopressor agents, which should be used in the lowest possible doses. Higher vasopressor doses are associated with poorer survival⁴⁸; this represents both more severe underlying hemodynamic derangement and direct toxic effects.

Inotropic agents have a central role in treatment because the initiating event involves contractile failure. Unfortunately, inotropes increase myocardial ATP consumption such that short-term hemodynamic improvement occurs at the cost of increased oxygen demand when the heart is already failing and supply is already limited. Still, use of inotropic and vasopressor agents is always required to maintain coronary and systemic perfusion until (and often after) an IABP is placed or until shock resolves. Data on comparison of vasopressors are scant. The American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend norepinephrine for more severe hypotension because of its high potency.⁴⁴ Although both dopamine and norepinephrine have inotropic properties, dobutamine is often needed in addition. Pharmacological treatments that warrant further investigation include vasopressin; levosimendan, a calcium-sensitizing agent that has so far shown little additional value in randomized heart failure trials^{49,50}; and/or activated protein C, which has been tried in conjunction with mechanical support in myocarditis patients.⁵¹

Mechanical Support: IABP

Intra-aortic balloon counterpulsation has long been the mainstay of mechanical therapy for CS. Use of an IABP improves coronary and peripheral perfusion via diastolic balloon inflation and augments LV performance via systolic balloon deflation with an acute decrease in afterload. Accurate timing of inflation and deflation provides optimal support. Not every patient has a hemodynamic response to IABP; response predicts better outcome.⁵² IABP support should be instituted as quickly as possible, even before any transfer for revascularization if a skilled operator is available and insertion can be performed quickly.

In the large National Registry of Myocardial Infarction, IABP use was independently associated with survival at centers with higher rates of IABP use, whether PCI, fibrinolytic therapy, or no reperfusion had been used⁵³; however, no completed trials demonstrate benefit. Complications associated with IABP are less common in the modern era; in the largest series, the overall and major complication rates were 7.2% and 2.8%, respectively.⁵⁴ Risk factors for complications include female sex, small body size, and peripheral vascular disease.

Reperfusion

The survival benefit of early revascularization in CS, reported in several observational studies, was shown convincingly in the randomized SHOCK trial, which found a 13% absolute increase in 1-year survival in patients assigned to early revascularization.^{11,55} This corresponds to a number needed to treat of <8 patients to save 1 life. The benefit was similar in the incomplete, randomized Swiss Multicenter Study of Angioplasty for Shock.⁵⁶ Numerous registry studies have confirmed the survival advantage of early revascularization, whether percutaneous or surgical, in the young and the elderly. Thrombolytic therapy is less effective but is indicated when PCI is impossible or if a delay has occurred in transport for PCI and when MI and CS onset were within 3 hours.

Timing of PCI

As in MI without shock, earlier revascularization is better in CS. Presentation 0 to 6 hours after symptom onset was associated with the lowest mortality among CS patients undergoing primary PCI in the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK) registry, in which door-to-angiography times were <90 minutes in approximately three fourths of patients.⁵⁷ In the SHOCK trial, there appeared to be increasing long-term mortality as time to revascularization increased from 0 to 8 hours.⁵⁵ However, there is a survival benefit as long as 48 hours after MI and 18 hours after shock onset.

Stenting and Glycoprotein IIb/IIIa Inhibition

Stenting and glycoprotein IIb/IIIa inhibitors were independently associated with improved outcomes in patients undergoing PCI for CS in multiple registries, including the large ACC-National Cardiovascular Data Registry.⁵⁸ A trend toward benefit of abciximab was noted in a small subset of STEMI patients with CS undergoing PCI in a randomized trial.^{58a}




Figure 4. Algorithm for revascularization strategy in cardiogenic shock, from ACC/AHA guidelines.^{42,44} Whether shock onset occurs early or late after MI, rapid IABP placement and angiography are recommended. Immediate CABG is the preferred method of revascularization when severe triple-vessel or left main disease is present and should be performed as needed when VSR or severe mitral regurgitation exists. PCI of the infarct-related artery is recommended in the case of single- or double-vessel disease or moderate triple-vessel disease and when CABG is not possible for patients with more extensive disease. CAD indicates coronary artery disease; IRA, infarct-related artery.

Revascularization Approach: Surgery or PCI

Revascularization in the SHOCK trial could be percutaneous or surgical. Thirty-seven percent of patients assigned to the early revascularization strategy underwent CABG at a median of 2.7 hours after randomization.⁵⁹ Despite a higher prevalence of triple-vessel or left main disease and diabetes mellitus in patients who underwent CABG compared with PCI, survival and quality of life were similar.^{59,60} The rate of emergency CABG in CS is much lower in the community (<10%).⁴

Survival in patients with CS who have CABG may improve further with advancing surgical techniques. In a series of CS patients undergoing surgery, a trend toward better survival with beating heart techniques was present despite the use of slightly lower numbers of grafts.⁶¹ A left internal mammary artery graft was used in >98% of patients with CS in this study as opposed to 15.2% in SHOCK. This latter point could be of particular importance when one considers the potential for long-term survival in CS patients.

Multivessel Disease

The optimal revascularization strategy (ie, percutaneous or surgical, single or multivessel PCI) for patients with multivessel coronary artery disease and CS is not clear. This is of particular importance because multivessel disease is common; 87% of patients in SHOCK had multivessel disease.⁶² In some patients, coronary anatomy may be most amenable to CABG. It is not clear whether multivessel PCI is useful in CS. In SHOCK, the rate of multivessel PCI increased over the study period, which perhaps suggests that operators gained experience with PCI in CS patients; however, this small subset had a worse adjusted outcome than those with single-vessel PCI.⁶³ Short-term PCI of non-infarct-related artery vessels during MI is associated with more complications than

delayed non-infarct-related artery treatment.⁶⁴ In clinical practice, as in the SHOCK trial,⁵⁹ multivessel PCI is performed in approximately one fourth of patients with CS undergoing PCI. This translates into multivessel PCI in just over one third of those with multivessel disease.

Figure 4 depicts the ACC/AHA guidelines for revascularization in shock, which recommend surgery for extensive disease. Staged multivessel PCI may be performed if surgery is not an option, and a single-stage procedure may be considered if the patient remains in shock after PCI of the infarct-related artery and if the other vessel has a lesion that is flow limiting at rest and supplies a large risk region.

Risk Stratification and Targeting the Population for Revascularization

Mortality due to CS is not as high as many clinicians may believe and is ≈50% in the modern era, far lower than historic figures of 80% to 90%. Mortality can range from 10% to 80% depending on demographic, clinical, and hemodynamic factors. These factors include age, clinical signs of peripheral hypoperfusion, anoxic brain damage, LVEF, and stroke work. Female sex does not appear to be an independent predictor of poor outcome. Hemodynamic data are predictive of short-term but not long-term mortality. Factors associated with long-term survival in the SHOCK trial are shown in the Table. Revascularization provides benefit at every level of risk.⁶⁵ Among CS patients undergoing PCI, age, time from symptom onset to PCI, and post-PCI TIMI (Thrombolysis In Myocardial Infarction) flow grade are independent predictors of mortality.^{55,58} Mortality due to CS is on the decline in the United States and Europe in parallel with increasing use of revascularization.^{3,4,57}

The initial misperception that elderly patients do not benefit from PCI arose from the interaction between treat-

Table. SHOCK Trial Long-Term Survival Rates by Subgroup

Subgroup	No.	3-Year Survival, %	6-Year Survival, %	P*
Age <75 y	246	38.2	27.6	0.063
Age ≥75 y	56	20.6	20.6	...
Males	205	33.9	24.0	0.931
Females	97	36.9	30.9	...
Shock on admission	41	24.8	12.4	0.016
No shock on admission	230	36.7	28.5	...
Prior MI	98	22.9	15.3	0.005
No prior MI	204	40.2	31.0	...
History of hypertension	137	30.5	18.2	0.027
No history of hypertension	159	39.6	34.0	...
Anterior MI	177	33.6	25.0	0.209
Nonanterior MI	119	36.8	29.8	...
Systemic hypoperfusion rapidly reversed with IABP	90	43.3	32.9	<0.0001
Systemic hypoperfusion not rapidly reversed	131	20.6	16.5	...
CI <2.0 L · min ⁻¹ · min ⁻²	177	33.4	26.1	0.103
CI ≥2.0 L · min ⁻¹ · min ⁻²	83	44.3	37.3	...
PCWP <25 mm Hg	143	43.8	33.4	0.010
PCWP ≥25 mm Hg	126	28.3	22.0	...
LVEF <25%	58	29.9	19.2	0.002
LVEF ≥25%	114	50.8	40.9	...
Single-vessel disease	31	64.5	49.2	0.044
Multivessel disease	208	37.6	28.2	...
Baseline creatinine <1.9 mg/dL†	205	37.9	29.5	0.0002
Baseline creatinine ≥1.9 mg/dL	53	13.8	13.8	...
Thrombolytic therapy at index MI	170	39.3	31.4	0.016
No thrombolytic therapy at index MI	132	28.8	18.6	...
Left main stenosis ≥50%‡	50	31.6	28.9	0.066
Left main stenosis <50%	188	44.6	32.2	...

Table provided by Dr Lynn Sleeper; data analyzed for Hochman et al.⁵⁵ Hemodynamic values from time of shock diagnosis while on support measures. No significant interaction was present between any subgroup factor and treatment assignment. Multivariate modeling revealed that older age ($P=0.007$), shock on admission ($P=0.012$), creatinine >1.9 mg/dL ($P<0.0001$), a history of hypertension ($P=0.032$), and noninferior MI location ($P=0.022$) were independent risk factors for lower survival rates in a clinical model ($N=230$). The model that also incorporated hemodynamic measurements and LVEF ($N=148$) demonstrated that only older age ($P=0.035$), lower LVEF ($P<0.0001$), and creatinine >1.9 mg/dL ($P=0.012$) were independently associated with death. CI indicates cardiac index; PCWP, pulmonary capillary wedge pressure.

*Log-rank P value comparing survival curves between subgroups.

†Quartile 4 vs quartiles 1 through 3 for creatinine.

‡Coronary anatomy was available for 239 of 302 patients. The single vessel disease group includes 5 patients with nonsignificant coronary artery disease.

ment effect and age in the SHOCK trial.¹¹ The apparent lack of benefit for the elderly in the SHOCK trial was likely due to imbalances in baseline ejection fraction between groups. Several studies, including the SHOCK registry, have shown a consistent benefit of revascularization in elderly patients selected for it (20% to 33%), which suggests that clinicians are capable of identifying those older patients who are appropriate for revascularization.⁶⁶

ACC/AHA guidelines recommend early revascularization in CS for those <75 years of age (class I) and for suitable candidates ≥75 years of age (class IIa).⁴⁴ Rapid transfer is also recommended for most patients who present to hospitals without revascularization capability (Figure 4). Unfortunately, real-world revascularization rates range from 27% to 54%.⁴ Revascularization will likely be more widely used if clinicians recognize that benefit exists despite high risk and if they need not fear adverse consequences of state and local public mortality reporting.⁶⁷ New York State will analyze PCI and CABG mortality rates for CS separately and will exclude them from public reporting for a 2-year period.

Healthcare policy planners may consider patients with multiple risk indicators to be at such high risk that in a resource-limited system, it may not be feasible to perform PCI or CABG when the associated mortality rate is >80%. However, models demonstrate that benefit is derived across the risk spectrum. A group exists for whom additional treatment is futile, particularly when irreversible multiple end-organ failure or anoxic brain damage has occurred. Clearly, a revascularization approach must be individualized. We propose that the most important consideration, especially for the elderly, is functional status before the index event.

Total Circulatory Support: LV Assist Devices and Extracorporeal Life Support

Temporary mechanical circulatory support with LV assist devices (LVADs) is theoretically appealing to interrupt the vicious spiral of ischemia, hypotension, and myocardial dysfunction, allowing for recovery of stunned and hibernating myocardium and reversal of neurohormonal derangements. Device-related complications and irreversible organ failure remain major limitations.

LVAD support involves circulation of oxygenated blood through a device that drains blood from the left side of the heart and returns blood to the systemic arteries with pulsatile or continuous flow. Surgically implanted LVADs remove blood through a cannula placed at the LV apex and return blood to the ascending aorta. Percutaneous LVADs are also available. The TandemHeart (Cardiac Assist, Inc, Pittsburgh, Pa) removes blood from the left atrium using a cannula placed through the femoral vein and into the left atrium via transseptal puncture. Blood is then returned to a systemic artery, usually the femoral, with retrograde perfusion of the abdominal and thoracic aorta. Another percutaneous device, the Impella (Abiomed, Inc, Danvers, Mass), is placed across the aortic valve and is under investigation.⁶⁸ Extracorporeal life support (ECLS) involves extracorporeal circulation of blood through a membrane oxygenator, which relieves both the right and left heart and the lungs of part of their workload. Anticoagulation is required for extracorporeal life support

and for percutaneous LVADs but may be optional with surgically placed LVADs.

Extracorporeal life support and LVAD have been used sequentially in CS patients, usually as a bridge to heart transplantation.⁶⁹ In the largest reported LVAD series to date, 74% of 49 patients survived to transplantation, and 87% of transplanted patients survived to hospital discharge after receiving a variety of surgical LVADs.⁷⁰ The risk of bleeding is no higher after MI than in chronic heart failure despite placement of a cannula in the LV apex, which may be necrotic.⁷⁰

Although early LVAD and extracorporeal life support use followed by transplantation has been proposed as an alternative approach to urgent revascularization, direct comparison has not been systematic, and observational studies have had conflicting results. The role of combined treatment is not clear. A nonrandomized comparison of “aggressive” and “conservative” approaches found that early use of circulatory support and heart transplantation was associated with better survival than selection for revascularization,⁷¹ but a study of surgical treatment with LVAD with or without CABG found that mortality was higher in patients who had CABG with LVAD placement early after MI.⁷²

Two randomized trials of the TandemHeart versus IABP in CS complicating MI have been conducted.^{73,74} Hemodynamic improvement was better in LVAD groups, but a higher rate of multiorgan system dysfunction was observed in the LVAD group with a clinical profile that suggested SIRS, and the mortality rates were the same.

Perhaps most promising given the limited supply of donor organs is the use of LVADs as destination therapy for viable patients who may or may not be transplant candidates.^{75,76} Randomized trials are needed for a more complete assessment of the role of different circulatory support strategies in CS.

Treatment of CS Due to Mechanical Complications

Mechanical complications of MI, including rupture of the ventricular septum, free wall, or papillary muscles, cause 12% of CS cases; of these, ventricular septal rupture (VSR) has the highest mortality, 87%.⁷⁷ Women and the elderly are at increased risk,⁷⁸ and, at least among elderly patients, risk is higher with thrombolysis than with primary PCI.⁷⁹ In general, thrombolysis shifts the time course of rupture, with an increase in early and a decrease in later rupture such that the overall rate is reduced.⁸⁰ Rupture should be strongly suspected in patients with small infarct size and shock. Echocardiography is instrumental in the diagnosis.

Acute mitral regurgitation may cause or exacerbate CS. Mitral regurgitation may occur due to papillary muscle/chordal rupture or may be due to acute LV dilation with tethering of the mitral apparatus and failure of coaptation. Papillary muscle rupture is more common with inferior infarction.

Timely repair of myocardial rupture associated with CS is critical for survival. It was previously thought that optimal timing involves a balance of operating before the onset of multiorgan system failure with delaying surgery to allow

scarring of involved myocardium for better stability of repair. Repair of VSR and free wall rupture present technical difficulties to the surgeon because of the need to suture in an area of necrotic myocardium. Repair of papillary muscle rupture does not involve necrotic myocardium in suture lines, and mortality associated with this repair is lower. The unpredictability of rapid deterioration and death with VSR and papillary muscle rupture makes early surgery necessary even though there may be apparent hemodynamic stabilization with IABP.⁸¹ A subgroup of patients with VSR exists for whom surgery is futile because mortality approaches 100%; this includes the very elderly and patients with poor RV function. RV function is a more important determinant of outcome in VSR than LV function.⁸¹

Investigation is ongoing to find new techniques to reduce this very high operative risk. Newer off-pump techniques include external septal plication for VSR⁸² and repair of free wall rupture with surgical glue and a Gore-Tex patch.⁸³ Percutaneous VSR repair has been reported for simple and complex defects⁸⁴ and after failure of surgical repair.⁸⁵ Percutaneous repair is accomplished via venous access with septal occluders that consist of 2 disks connected by a waist. Devices are available in a wide range of sizes. One limitation of this approach is that ventricular septal defect sizing may be technically difficult, and healing of the infarcted myocardium may increase the size of the ventricular septal defect, leading to device malapposition or even embolization.⁸⁶ The use of devices with diameter larger than the ventricular septal defect has been associated with relatively good outcome.⁸⁷

Management of Special Conditions

The treatment of certain conditions that lead to CS is marked by important differences from management of CS due to LV failure. The recognition of LV outflow obstruction is critical in patients with hypotension, because diuretics and inotropic agents exacerbate obstruction. Treatment of CS with hypertrophic obstructive cardiomyopathy includes volume resuscitation and β -blockade. Pure α -agonists may also be used to increase afterload, increasing cavity size and decreasing obstruction. Outflow obstruction may also be seen in some cases of tako-tsubo cardiomyopathy when extensive akinesis/dyskinesis of apical zones occurs with hyperkinesis of remaining myocardium. Therapy is guided by echocardiography and clinical response. IABP may provide circulatory support. β -Blockade is often not indicated in this circumstance because it exacerbates LV dysfunction. α -Agonists may be helpful for vasopressor effect until myocardial recovery, which typically occurs if the patient can be supported. Inotropes improve function in the stunned myocardium and may therefore be useful when outflow obstruction is not visualized. Low doses should be initiated, with careful monitoring of the response.

Long-Term Survival and Quality of Life

Long-term survival data from the SHOCK trial were reported recently. Remarkably, the 3- and 6-year survival rates in the early revascularization group were 41.4% and 32.8% with persistence of treatment benefit⁵⁵ (Figure 5). These rates are similar to or better than 30-day survival rates reported in




Figure 5. Long-term follow-up of the SHOCK trial cohort.⁵⁵ Early revascularization (ERV) is associated with sustained benefit. The annualized mortality rate was lower among 1-year survivors who had been randomized to revascularization than among those assigned to medical stabilization (IMS), which indicates a continued protective effect of early revascularization. Reprinted from Hochman et al,⁵⁵ with permission from the publisher. Copyright © 2006, American Medical Association. All rights reserved.

studies in which patients did not routinely receive invasive therapy⁸⁸ and similar to 5-year survival rates for many forms of cancer. These findings are consistent with the 55% 11-year survival rate observed in the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO-I) trial among 30-day CS survivors. Furthermore, in GUSTO-I, annual mortality rates after 1 year (2% to 4%) were similar for those with and without shock.⁸⁹

At least as important as long-term survival is quality of life in survivors. Again, this is far better than many clinicians would suspect. Already at 2 weeks after discharge, 75.9% of patients assigned to revascularization and 62.5% of patients assigned to medical stabilization in the SHOCK trial were in New York Heart Association functional class I to II (Figure 6).⁶⁰ Among patients who were in functional class III to IV at 2 weeks, 55% of survivors improved to class I to II by 1 year. Similarly, in a series of CS patients treated with early revascularization, 80% of survivors were completely asymptomatic at a median of 18 months, and all were in functional class I to II.⁹⁰ Bicycle exercise testing in a subgroup showed age-appropriate exercise capacity in all. In a series of CS patients treated with circulatory support, nearly all performed activities of daily living >1 year after the event, and some had even returned to full-time employment.⁹¹

Conclusions

CS is a treatable illness with a reasonable chance for full recovery. The CS literature has traditionally focused on the very high mortality associated with this diagnosis. It is important to recognize that although patients with CS are at very high risk for early death, great potential exists for salvage. Recent evidence challenges the notion that patients with CS are a “lost cause.” In fact, an early invasive approach can increase short- and long-term survival and can result in excellent quality of life. Revascularization is associated with some benefit at every level of risk. Taken together, these survival and quality-of-life data should prompt consideration of aggressive early care for even highly unstable patients and additional clinical trials of new pharmacological and mechan-




Figure 6. Functional status in the SHOCK trial.⁶⁰ The majority of patients who survived 2 weeks after discharge had good functional status (and quality of life) at that time point. Functional status continued to be good up to 1 year after the event. ERV indicates early revascularization; IMS, initial medical stabilization. Reprinted from Sleeper et al,⁶⁰ copyright © 2005, with permission from The American College of Cardiology Foundation.

ical therapies. Clinicians and researchers must focus on the potential for full recovery if we are truly to make an impact on the burden of this disease. Prevention with very early reperfusion therapy remains the major goal.

Disclosures

The authors disclose previous research funding from ArgiNOx. Dr Hochman has received modest consulting fees from Datascope and from Eli Lilly for serving on a steering committee. She also serves on a steering committee for a study funded by Schering Plough.

References

- Giannuzzi P, Imbarato A, Temporelli PL, de Vito F, Silva PL, Scapellato F, Giordano A. Doppler-derived mitral deceleration time of early filling as a strong predictor of pulmonary capillary wedge pressure in postinfarction patients with left ventricular systolic dysfunction. *J Am Coll Cardiol*. 1994;23:1630–1637.
- Gianni M, Dentali F, Grandi AM, Sumner G, Hiralal R, Lonn E. Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. *Eur Heart J*. 2006;27:1523–1529.
- Fox KA, Anderson FA Jr, Dabbous OH, Steg PG, Lopez-Sendon J, Van de Werf F, Budaj A, Gurfinkel EP, Goodman SG, Brieger D. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE). *Heart*. 2007;93:177–182.
- Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. *JAMA*. 2005;294:448–454.
- Hasdai D, Harrington RA, Hochman JS, Califf RM, Battler A, Box JW, Simoons ML, Deckers J, Topol EJ, Holmes DR Jr. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. *J Am Coll Cardiol*. 2000;36:685–692.
- Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smolter S, Wilson M, Wolf P. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*. 2006;113:e85–e151.
- Steg PG, Bonney E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, Leizorovicz A, Touboul P. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. *Circulation*. 2003;108:2851–2856.
- Lindholm MG, Kober L, Boesgaard S, Torp-Pedersen C, Aldershvile J. Cardiogenic shock complicating acute myocardial infarction: prog-

- nostic impact of early and late shock development. *Eur Heart J*. 2003; 24:258–265.
9. Beyersdorf F, Buckberg GD, Acar C, Okamoto F, Sjostrand F, Young H, Bugyi HI, Allen BS. Cardiogenic shock after acute coronary occlusion: pathogenesis, early diagnosis, and treatment. *Thorac Cardiovasc Surg*. 1989;37:28–36.
 10. Ramanathan K, Harkness SM, Nayar AC, Cosmi JE, Sleeper LS, White HD, Davidoff R, Hochman JS. Cardiogenic shock in patients with preserved left ventricular systolic function: characteristics and insight into mechanisms. *J Am Coll Cardiol*. 2004;43:241A.
 11. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH. Early revascularization in acute myocardial infarction complicated by cardiogenic shock: SHOCK Investigators: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. *N Engl J Med*. 1999;341:625–634.
 12. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet*. 2001;357:1385–1390.
 13. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. *N Engl J Med*. 2004;351:2481–2488.
 14. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med*. 2002;346:877–883.
 15. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. *Circulation*. 2002;106:2194–2199.
 16. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med*. 2003; 349:1893–1906.
 17. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. *Lancet*. 2003;362:759–766.
 18. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. *Lancet*. 2000;355:1582–1587.
 19. Pitt B, White H, Nicolau J, Martinez F, Gheorghide M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. *J Am Coll Cardiol*. 2005;46:425–431.
 20. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. *N Engl J Med*. 1999;341:709–717.
 21. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. *Lancet*. 2003;362:7–13.
 22. Stevenson LW, Miller LW, Desvigne-Nickens P, Ascheim DD, Parides MK, Renlund DG, Oren RM, Krueger SK, Costanzo MR, Wann LS, Levitan RG, Mancini D. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). *Circulation*. 2004;110:975–981.
 23. Yehudai L, Reynolds HR, Schwarz SA, Harkness SM, Picard MH, Davidoff R, Hochman JS. Serial echocardiograms in patients with cardiogenic shock: analysis of the SHOCK Trial. *J Am Coll Cardiol*. 2006; 47(suppl A):111A.
 24. Reynolds HR, Anand SK, Fox JM, Harkness S, Dzavik V, White HD, Webb JG, Gin K, Hochman JS, Picard MH. Restrictive physiology in cardiogenic shock: observations from echocardiography. *Am Heart J*. 2006;151:890 e9–e15.
 25. Picard MH, Davidoff R, Sleeper LA, Mendes LA, Thompson CR, Dzavik V, Steingart R, Gin K, White HD, Hochman JS. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. *Circulation*. 2003;107:279–284.
 26. Jacobs AK, Leopold JA, Bates E, Mendes LA, Sleeper LA, White H, Davidoff R, Boland J, Modur S, Forman R, Hochman JS. Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. *J Am Coll Cardiol*. 2003;41:1273–1279.
 27. Brookes C, Ravn H, White P, Moeldrup U, Oldershaw P, Redington A. Acute right ventricular dilatation in response to ischemia significantly impairs left ventricular systolic performance. *Circulation*. 1999;100: 761–767.
 28. Berisha S, Kastrati A, Goda A, Popa Y. Optimal value of filling pressure in the right side of the heart in acute right ventricular infarction. *Br Heart J*. 1990;63:98–102.
 29. Koksaka S, Menon V, Lowe AM, Lange M, Dzavik V, Sleeper LA, Hochman JS. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. *Arch Intern Med*. 2005;165:1643–1650.
 30. Brunkhorst FM, Clark AL, Forycki ZF, Anker SD. Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation. *Int J Cardiol*. 1999;72:3–10.
 31. Theroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, Nicolau JC, Lavoie J, Luong TM, Burchenal J, Granger CB. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. *Eur Heart J*. 2005;26:1964–1970.
 32. Zhang C, Xu X, Potter BJ, Wang W, Kuo L, Michael L, Bagby GJ, Chilian WM. TNF-alpha contributes to endothelial dysfunction in ischemia/reperfusion injury. *Arterioscler Thromb Vasc Biol*. 2006;26: 475–480.
 33. Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. *Circulation*. 2003;108: 1184–1190.
 34. Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D Jr, O'Neill WW, Todaro TG, Vahanian A, Van de Werf F. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. *JAMA*. 2007;297:43–51.
 35. TRIUMPH Investigators. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. *JAMA*. 2007;297:1657–1666.
 36. Dzavik V, Cotter G, Reynolds HR, Alexander JH, Ramanathan K, Stebbins AL, Hathaway D, Farkouh ME, Ohman EM, Baran DA, Prondzinsky R, Panza JA, Cantor WJ, Vered Z, Buller CE, Kleiman NS, Webb JG, Holmes DR, Parrillo JE, Hazen SL, Gross SS, Harrington RA, Hochman JS. Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. *Eur Heart J*. 2007;28:1109–1116.
 37. Jeger RV, Harkness SM, Ramanathan K, Buller CE, Pfisterer ME, Sleeper LA, Hochman JS. Emergency revascularization in patients with cardiogenic shock on admission: a report from the SHOCK trial and registry. *Eur Heart J*. 2006;27:664–670.
 38. Meine TJ, Roe MT, Chen AY, Patel MR, Washam JB, Ohman EM, Peacock WF, Pollack CV Jr, Gibler WB, Peterson ED. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. *Am Heart J*. 2005;149:1043–1049.
 39. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral aspirin, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. *Lancet*. 1995;345:669–685.
 40. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. *Circulation*. 1998;97:2202–2212.

41. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet*. 2005; 366:1622–1632.
42. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. *Circulation*. 2003;107:2998–3002.
43. Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock. *Ann Intern Med*. 1999;131:47–59.
44. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). *Circulation*. 2004;110:588–636.
45. Fincke R, Hochman JS, Lowe AM, Menon V, Slater JN, Webb JG, LeJemtel TH, Cotter G. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. *J Am Coll Cardiol*. 2004;44:340–348.
46. Connors AF Jr, Speroff T, Dawson NV, Thomas C, Harrell FE Jr, Wagner D, Desbiens N, Goldman L, Wu AW, Califf RM, Fulkerson WJ Jr, Vidaillet H, Broste S, Bellamy P, Lynn J, Knaus WA; SUPPORT Investigators. The effectiveness of right heart catheterization in the initial care of critically ill patients. *JAMA*. 1996;276:889–897.
47. Cohen MG, Kelly RV, Kong DF, Menon V, Shah M, Ferreira J, Pieper KS, Criger D, Poggio R, Ohman EM, Gore J, Califf RM, Granger CB. Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials. *Am J Med*. 2005;118: 482–488.
48. Valente S, Lazzeri C, Vecchio S, Giglioli C, Margheri M, Bernardo P, Comeglio M, Chiochini S, Gensini GF. Predictors of in-hospital mortality after percutaneous coronary intervention for cardiogenic shock. *Int J Cardiol*. 2007;114:176–182.
49. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. *JAMA*. 2007;297:1883–1891.
50. Packer M. The Randomized multicenter Evaluation of Intravenous leVosimendan Efficacy 2 (REVIVE-2) trial. Paper presented at: Late-Breaking Clinical Trials, Annual Scientific Sessions of the American Heart Association; November 13–16, 2005; Dallas, Texas.
51. Tsai TP, Tsao SM, Wu YL, Yu JM, Chan KC, Ueng KC. Managing life threatening viral myocarditis with dilated cardiomyopathy by drotrecogin alfa and circulatory assisted devices. *Chest*. 2005;128:275S.
52. Ramanathan K, Cosmi J, Harkness SM, French JK, Farkouh ME, Sleeper LA, Dzavik V, Hochman JS. Reversal of systemic hypoperfusion following intra aortic balloon pumping is associated with improved 30-day survival independent of early revascularization in cardiogenic shock complicating an acute myocardial infarction. *Circulation*. 2003;108(suppl 1):I-672.
53. Chen EW, Canto JG, Parsons LS, Peterson ED, Littrell KA, Every NR, Gibson CM, Hochman JS, Ohman EM, Cheeks M, Barron HV. Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. *Circulation*. 2003;108:951–957.
54. Urban PM, Freedman RJ, Ohman EM, Stone GW, Christenson JT, Cohen M, Miller MF, Joseph DL, Bynum DZ, Ferguson JJ III. In-hospital mortality associated with the use of intra-aortic balloon counterpulsation. *Am J Cardiol*. 2004;94:181–185.
55. Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, Col J, White HD. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. *JAMA*. 2006;295:2511–2515.
56. Urban P, Stauffer JC, Bleed D, Khatchatrian N, Amann W, Bertel O, van den Brand M, Danchin N, Kaufmann U, Meier B, Machecourt J, Pfisterer M. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction: the (Swiss) Multicenter Trial of Angioplasty for Shock: (S)MASH. *Eur Heart J*. 1999;20:1030–1038.
57. Zeymer U, Vogt A, Zahn R, Weber MA, Tebbe U, Gottwik M, Bonzel T, Senes J, Neuhaus KL. Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI): results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK). *Eur Heart J*. 2004;25: 322–328.
58. Klein LW, Shaw RE, Krone RJ, Brindis RG, Anderson HV, Block PC, McKay CR, Hewitt K, Weintraub WS. Mortality after emergent percutaneous coronary intervention in cardiogenic shock secondary to acute myocardial infarction and usefulness of a mortality prediction model. *Am J Cardiol*. 2005;96:35–41.
- 58a. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansieri M, Choussat R, Pinton P; for the ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. *N Engl J Med*. 2001;344:1895–1903.
59. White HD, Assmann SF, Sanborn TA, Jacobs AK, Webb JG, Sleeper LA, Wong CK, Stewart JT, Aylward PE, Wong SC, Hochman JS. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial. *Circulation*. 2005;112: 1992–2001.
60. Sleeper LA, Ramanathan K, Picard MH, Lejemtel TH, White HD, Dzavik V, Tormey D, Avis NE, Hochman JS. Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. *J Am Coll Cardiol*. 2005;46:266–273.
61. Rastan AJ, Eckenstein JJ, Hentschel B, Funkat AK, Gummert JF, Doll N, Walther T, Falk V, Mohr FW. Emergency coronary artery bypass graft surgery for acute coronary syndrome: beating heart versus conventional cardioplegic cardiac arrest strategies. *Circulation*. 2006;114(suppl 1): I-477–I-485.
62. Sanborn TA, Sleeper LA, Webb JG, French JK, Bergman G, Parikh M, Wong SC, Boland J, Pfisterer M, Slater JN, Sharma S, Hochman JS. Correlates of one-year survival in patients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. *J Am Coll Cardiol*. 2003;42:1373–1379.
63. Webb JG, Lowe AM, Sanborn TA, White HD, Sleeper LA, Carere RG, Buller CE, Wong SC, Boland J, Dzavik V, Porway M, Pate G, Bergman G, Hochman JS. Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. *J Am Coll Cardiol*. 2003;42:1380–1386.
64. Corpus RA, House JA, Marso SP, Grantham JA, Huber KC Jr, Laster SB, Johnson WL, Daniels WC, Barth CW, Giorgi LV, Rutherford BD. Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction. *Am Heart J*. 2004;148:493–500.
65. Sleeper LA, Jacobs AK, LeJemtel TH, Webb JG, Hochman JS. A mortality model and severity scoring system for cardiogenic shock complicating acute myocardial infarction. *Circulation*. 2000;102(suppl II): II-795.
66. Dzavik V, Sleeper LA, Cocke TP, Moscucci M, Saucedo J, Hosat S, Jiang X, Slater J, LeJemtel T, Hochman JS. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. *Eur Heart J*. 2003;24:828–837.
67. Moscucci M, Eagle KA, Share D, Smith D, De Franco AC, O'Donnell M, Kline-Rogers E, Jani SM, Brown DL. Public reporting and case selection for percutaneous coronary interventions: an analysis from two large multicenter percutaneous coronary intervention databases. *J Am Coll Cardiol*. 2005;45:1759–1765.
68. Henriques JP, Rimmelink M, Baan J Jr, van der Schaaf RJ, Vis MM, Koch KT, Scholten EW, de Mol BA, Tijssen JG, Piek JJ, de Winter RJ. Safety and feasibility of elective high-risk percutaneous coronary intervention procedures with left ventricular support of the Impella Recover LP 2.5. *Am J Cardiol*. 2006;97:990–992.
69. Hoefer D, Ruttman E, Poelzl G, Kilo J, Hoermann C, Margreiter R, Laufer G, Antretter H. Outcome evaluation of the bridge-to-bridge concept in patients with cardiogenic shock. *Ann Thorac Surg*. 2006;82: 28–33.
70. Leshower BG, Gleason TG, O'Hara ML, Pochettino A, Woo YJ, Morris RJ, Gardner TJ, Acker MA. Safety and efficacy of left ventricular assist device support in postmyocardial infarction cardiogenic shock. *Ann Thorac Surg*. 2006;81:1365–1370.
71. Tayara W, Starling RC, Yamani MH, Wazni O, Jubran F, Smedira N. Improved survival after acute myocardial infarction complicated by cardiogenic shock with circulatory support and transplantation: comparing aggressive intervention with conservative treatment. *J Heart Lung Transplant*. 2006;25:504–509.
72. Dang NC, Topkara VK, Leacche M, John R, Byrne JG, Naka Y. Left ventricular assist device implantation after acute anterior wall myo-

- cardial infarction and cardiogenic shock: a two-center study. *J Thorac Cardiovasc Surg*. 2005;130:693–698.
73. Burkhoff D, Cohen H, Brunkhorst C, O'Neill WW. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. *Am Heart J*. 2006;152:469 e1–e8.
 74. Thiele H, Sick P, Boudriot E, Diederich KW, Hambrecht R, Niebauer J, Schuler G. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. *Eur Heart J*. 2005;26:1276–1283.
 75. Burkhoff D, O'Neill W, Brunkhorst C, Letts D, Lasorda D, Cohen HA. Feasibility study of the use of the TandemHeart percutaneous ventricular assist device for treatment of cardiogenic shock. *Catheter Cardiovasc Interv*. 2006;68:211–217.
 76. Meyns B, Dens J, Sergeant P, Herijgers P, Daenen W, Flameng W. Initial experiences with the Impella device in patients with cardiogenic shock: Impella support for cardiogenic shock. *Thorac Cardiovasc Surg*. 2003;51:312–317.
 77. Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA, Godfrey E, White HD, Lim J, LeJemtel T. Cardiogenic shock complicating acute myocardial infarction: etiologies, management and outcome: a report from the SHOCK Trial Registry: SHould we emergently revascularize Occluded Coronaries for cardiogenic shock? *J Am Coll Cardiol*. 2000;36:1063–1070.
 78. Menon V, Webb JG, Hillis LD, Sleeper LA, Abboud R, Dzavik V, Slater JN, Forman R, Monrad ES, Talley JD, Hochman JS. Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: a report from the SHOCK Trial Registry: SHould we emergently revascularize Occluded Coronaries in cardiogenic shock? *J Am Coll Cardiol*. 2000;36:1110–1116.
 79. Bueno H, Martinez-Selles M, Perez-David E, Lopez-Palop R. Effect of thrombolytic therapy on the risk of cardiac rupture and mortality in older patients with first acute myocardial infarction. *Eur Heart J*. 2005;26:1705–1711.
 80. Becker RC, Charlesworth A, Wilcox RG, Hampton J, Skene A, Gore JM, Topol EJ. Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) study. *J Am Coll Cardiol*. 1995;25:1063–1068.
 81. Radford MJ, Johnson RA, Daggett WM Jr, Fallon JT, Buckley MJ, Gold HK, Leinbach RC. Ventricular septal rupture: a review of clinical and physiologic features and an analysis of survival. *Circulation*. 1981;64:545–553.
 82. Barker TA, Ng A, Morgan IS. Off-pump repair of a post-infarct ventricular septal defect: the “Hamburger procedure.” *J Cardiothorac Surg*. 2006;1:10.
 83. Canovas SJ, Lim E, Dalmau MJ, Bueno M, Buendia J, Hornero F, Gil O, Garcia R, Paya R, Perez J, Echanove I, Montero J. Midterm clinical and echocardiographic results with patch glue repair of left ventricular free wall rupture. *Circulation*. 2003;108(suppl II):II-237–II-240.
 84. Schiele TM, Kozlik-Feldmann R, Sohn HY, Stempfle HU, Kuchle C, Schopohl J, Theisen K, Leibig M, Klauss V. Transcatheter closure of a ruptured ventricular septum following inferior myocardial infarction and cardiogenic shock. *Catheter Cardiovasc Interv*. 2003;60:224–228.
 85. Cutfield NJ, Ruygrok PN, Wilson NJ, Raudkivi PJ, Greaves SC, Gentles TL, Kerr AJ. Transcatheter closure of a complex postmyocardial infarction ventricular septal defect after surgical patch dehiscence. *Intern Med J*. 2005;35:128–130.
 86. Lock JE, Block PC, McKay RG, Baim DS, Keane JF. Transcatheter closure of ventricular septal defects. *Circulation*. 1988;78:361–368.
 87. Holzer R, Balzer D, Amin Z, Ruiz CE, Feinstein J, Bass J, Vance M, Cao QL, Hijazi ZM. Transcatheter closure of postinfarction ventricular septal defects using the new Amplatzer muscular VSD occluder: results of a U.S. registry. *Catheter Cardiovasc Interv*. 2004;61:196–201.
 88. Dauerman HL, Goldberg RJ, White K, Gore JM, Sadiq I, Gurfinkel E, Budaj A, Lopez de Sa E, Lopez-Sendon J. Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. *Am J Cardiol*. 2002;90:838–842.
 89. Singh M, White J, Hasdai D, Hodgson PK, Berger PB, Topol EJ, Califf RM, Holmes DR. Long-term outcome and its predictors among patients with ST-elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. *J Am Coll Cardiol*. 2007;50:1752–1758.
 90. Ammann P, Straumann E, Naegeli B, Schuiki E, Frielingsdorf J, Gerber A, Bertel O. Long-term results after acute percutaneous transluminal coronary angioplasty in acute myocardial infarction and cardiogenic shock. *Int J Cardiol*. 2002;82:127–131.
 91. Smith C, Bellomo R, Raman JS, Matalanis G, Rosalion A, Buckmaster J, Hart G, Silvester W, Gutteridge GA, Smith B, Doolan L, Buxton BF. An extracorporeal membrane oxygenation-based approach to cardiogenic shock in an older population. *Ann Thorac Surg*. 2001;71:1421–1427.

KEY WORDS: cardiovascular diseases ■ myocardial infarction ■ outcomes research ■ shock

Cardiogenic Shock: Current Concepts and Improving Outcomes

Harmony R. Reynolds and Judith S. Hochman

Circulation. 2008;117:686-697

doi: 10.1161/CIRCULATIONAHA.106.613596

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2008 American Heart Association, Inc. All rights reserved.

Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://circ.ahajournals.org/content/117/5/686>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Circulation* is online at:
<http://circ.ahajournals.org/subscriptions/>